A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

por Machiels, Jean-Pascal, Salazar, Ramon, Rottey, Sylvie, Duran, Ignacio, Dirix, Luc, Geboes, Karen, Wilkinson-Blanc, Christine, Pover, Gillian, Alvis, Simon, Champion, Brian, Fisher, Kerry, McElwaine-Johnn, Hilary, Beadle, John, Calvo, Emiliano
Publicado 2019